Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Oct
24
2023
In This Case, "Primarily" Means A Small Fraction Allen Matkins Leck Gamble Mallory & Natsis LLP
Aug
23
2013
EPA Endorses New American Society for Testing and Materials (ASTM) Phase I Standard Allen Matkins Leck Gamble Mallory & Natsis LLP
Oct
13
2023
Governor Signs Bill Prohibiting Any Grocery Store Purchases Without Prior Written Notice To The Attorney General Allen Matkins Leck Gamble Mallory & Natsis LLP
Aug
12
2022
Despite Decriminalization Of Adult Recreational Use Of Marijuana, Court Finds Its Use Is Not Lawful Allen Matkins Leck Gamble Mallory & Natsis LLP
Aug
19
2022
Court Of Appeal Agrees $280 Pizza Oven Is Not A "Thing Of Value" Allen Matkins Leck Gamble Mallory & Natsis LLP
Jul
14
2014
Proposed Expanded Definition of Waters of the United States [VIDEO] Allen Matkins Leck Gamble Mallory & Natsis LLP
Aug
9
2013
California Supreme Court Weighs in on the California Environmental Quality Act (CEQA) Projected Baseline Issue Allen Matkins Leck Gamble Mallory & Natsis LLP
Sep
10
2018
Should One-A-Day Be Once-A-Day? Allen Matkins Leck Gamble Mallory & Natsis LLP
Apr
23
2014
Expanding the Definition of "Waters of the United States" – Environmental Protection Agency's (EPA) Proposed New Rule Allen Matkins Leck Gamble Mallory & Natsis LLP
May
15
2023
Does California Charter Law Breakers? Allen Matkins Leck Gamble Mallory & Natsis LLP
May
22
2013
Commercial and Residential Developers, Builders and Landlords Face New Storm Water Regulations Allen Matkins Leck Gamble Mallory & Natsis LLP
Dec
14
2017
Cannabizfile Comes To California Allen Matkins Leck Gamble Mallory & Natsis LLP
Jan
8
2019
California Legislature Mulls Cannabis Bank Charters Allen Matkins Leck Gamble Mallory & Natsis LLP
Apr
27
2013
Certain Residential Developments Exempt from California Environmental Quality Act (CEQA) Review: Greenhouse Gas Emission Issues Do Not Constitute New Information Allen Matkins Leck Gamble Mallory & Natsis LLP
Oct
4
2019
DBO Issues Guidance To Banks And Credit Unions Serving Cannabis Related Businesses Allen Matkins Leck Gamble Mallory & Natsis LLP
Jun
22
2022
A Truly Piscatory Exemption Allen Matkins Leck Gamble Mallory & Natsis LLP
Jan
7
2014
Clean Water Technology [AUDIO] Odin, Feldman & Pittleman, P.C.
Sep
16
2021
Virulent Fraud: Abusing COVID-19 Relaxed Telehealth Rules for Medicare Fraud Tycko & Zavareei LLP
Jan
25
2022
Phantom Participants with Real-World Ramifications: Clinical Drug Trial Data Falsification Tycko & Zavareei LLP
Jan
14
2020
Pharmaceutical Company Agrees To $54 Million To Settle False Claims Kickback Allegations Tycko & Zavareei LLP
Apr
12
2021
Whistleblower Reports Bristol-Myers Squibb Medicaid Drug Rebate Fraud, Resulting in $75 Million Recovery for The U.S. Government and States Tycko & Zavareei LLP
Oct
28
2014
Bostwick Laboratories Agrees to Pay U.S. Government $6.05 Million for Allegedly Violating the Anti-Kickback Statue; Whistleblower to Receive Reward Tycko & Zavareei LLP
May
9
2019
Co-Pay Kickbacks at Center of $122M in Settlement Fees for Alleged Medicare Fraud Tycko & Zavareei LLP
Dec
20
2017
Nationwide Pharmacy DaVita Rx to Pay $63.7 Million to Settle Healthcare Fraud Allegations Relating to Improper Billing Practices of Federal Healthcare Programs Tycko & Zavareei LLP
Jul
23
2018
AngioDynamics, Inc. Settles Qui Tam Lawsuit Alleging That It Lied About The Safety And Effectiveness Of LC Bead; Agrees To Pay $11.5 Million Tycko & Zavareei LLP
Dec
13
2014
New Jersey Medical Devices Company and Former CEO to Pay $80 Million for Alleged Illegal Distribution of Knee Replacement Apparatus Tycko & Zavareei LLP
Sep
16
2022
Whistleblower Receives $11 Million for Reporting Pharmaceutical Fraud Tycko & Zavareei LLP
Aug
28
2020
Biotech Testing Company to Pay $49 Million to Settle Allegations for Fraudulent Billing and Kickback Practices Tycko & Zavareei LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins